Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Protocol ID
ARST2031
Disease (Sub Disease)
Rhabdomyosarcoma
Diagnosis Stage
Newly diagnosed
Location
WA
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 50 Years
International registry ID's
NCT04994132
| Study Title | A Randomized Phase 3 Trial of Vinorelbine Dactinomycin and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) |
|---|---|
| Protocol ID | ARST2031 |
| Disease (Sub Disease) | Rhabdomyosarcoma |
| Diagnosis Stage | Newly diagnosed |
| Location | WA |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT04994132 |
| Trial Status | Open |
| Trial Open Date | 12/09/2023 |
| Sites | Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 50 Years |
| International registry ID's | NCT04994132 |